BofA analyst Craig Bijou upgraded Globus Medical (GMED) to Neutral from Underperform with a price target of $97, up from $80, after the company preannounced Q4 revenue that was 3% above the Street ...
AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback